Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Helsinn Therapeutics (U.S.), Inc
Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and cachexia. This placebo controlled study will evaluate the safety and efficacy of RC-1291 HCl in cancer patients with anorexia and cachexia.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Community-dwelling patients greater than 18 years of age with incurable, histologically diagnosed cancer.
Involuntary loss of body weight greater than 5% within the past 6 months
You may not be if
Presently hospitalized or in a nursing care facility.
Inability to increase food intake from secondary causes.
Liver disease
If female-pregnant, breast-feeding or of childbearing potential.
Clareo Health | Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia
